GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Immunic Inc.
Immunic is a biotech company developing oral medications for the treatment of autoimmune and inflammatory diseases. Its stock price is highly volatile and driven by news about the clinical trials of its lead drug.
Share prices of companies in the market segment - Pharma immune
Immunic is a biopharmaceutical company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis. We classify it as "Immune Pharmaceuticals." The chart below shows the overall dynamics of this cutting-edge segment.
Broad Market Index - GURU.Markets
Immunic is a German biotech company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Immunic shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
IMUX - Daily change in the company's share price Immunic Inc.
For Immunic, Inc., an immunology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter for risk assessment formulas on the System.GURU.Markets platform.
Daily change in the price of a set of shares in a market segment - Pharma immune
For Immunic, Inc., an immunology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter for risk assessment formulas on the GURU.Markets platform.
Daily change in the price of a broad market stock, index - GURU.Markets
Immunic is a biotech company working in the field of immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Immunic Inc.
Immunic, Inc.'s year-over-year performance is a story of developing oral medications for immune diseases. Its 12-month market cap is entirely dependent on clinical trial data for its lead candidate, which is being studied for multiple sclerosis and ulcerative colitis. Success could make it a significant alternative to injectables.
Annual dynamics of market capitalization of the market segment - Pharma immune
Immunic, Inc. is a clinical-stage biotech company developing drugs for the treatment of inflammatory and autoimmune diseases. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immunic is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor expectations for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Immunic Inc.
Immunic is a clinical-stage biotech company developing drugs to treat immune diseases. Its monthly performance directly reflects news from its clinical trials. Data from its lead drug, vidotolimod, is the main driver of volatility.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its leading candidates for the treatment of multiple sclerosis and ulcerative colitis in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immunic is a biotech company developing drugs to treat immune diseases. Its shares are currently awaiting clinical trial results. Their monthly performance is completely disconnected from the broader market, as the chart clearly illustrates, showing a reaction to scientific data rather than general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Immunic Inc.
Immunic, Inc., a clinical-stage biotech developing oral medications for autoimmune diseases, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials, reflecting the risks and hopes in this area.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Immunic develops oral medications for the treatment of chronic inflammatory and autoimmune diseases. The chart compares its volatile, news-driven performance with the broader immunology sector, helping to understand whether its scientific approach stands out from its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Immunic is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that Immunic's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
IMUX - Market capitalization of the company Immunic Inc.
Immunic's chart is a financial map of the fight against chronic inflammatory diseases. The company's market cap reflects the hopes for its oral medications for multiple sclerosis, ulcerative colitis, and psoriasis. Its dynamics are a barometer of progress in clinical trials and the belief that pills can replace injections in these areas.
IMUX - Share of the company's market capitalization Immunic Inc. within the market segment - Pharma immune
Immunic's market share in the immunology sector reflects its focus on developing oral medications for chronic inflammatory and autoimmune diseases. Its market share is based on the potential of its lead candidate, which could become a convenient alternative to injectable treatments.
Market capitalization of the market segment - Pharma immune
Immunic is a biotech company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. The chart below shows the market capitalization of this entire cutting-edge sector. Its dynamics reflect the hopes for new, more convenient treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Immunic is a biopharmaceutical company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. Its market capitalization reflects the potential of its developments. The chart below shows the economic weight of companies developing immune-related medications.
Book value capitalization of the company, segment and market as a whole
IMUX - Book value capitalization of the company Immunic Inc.
For Immunic, a biopharmaceutical company, book value represents its clinical research capital. The chart below shows its financial resources. This level is an indicator of its ability to fund the development of oral drugs for the treatment of autoimmune diseases.
IMUX - Share of the company's book capitalization Immunic Inc. within the market segment - Pharma immune
Immunic is a clinical-stage biotech company developing oral medications for immune diseases. Its value lies in its scientific platform. Its share of tangible assets will be minimal, which is typical for R&D companies whose main capital is intellectual property.
Market segment balance sheet capitalization - Pharma immune
Immunic is a clinical-stage biotech company. Its value is created in labs, not factories. It's a "lightweight" model based on intellectual capital. The chart below illustrates the extent to which the biopharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
Immunic's assets represent capital invested in clinical trials of oral medications for the treatment of chronic inflammatory and autoimmune diseases. The book value reflects resources devoted to developing convenient tablet alternatives to injectable biologics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Immunic Inc.
Immunic is a biotech company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. Its value lies in its pipeline. Its market capitalization is a bet on the success of its clinical programs. The chart shows the volatility typical of biotechs whose fate depends on research results.
Market to book capitalization ratio in a market segment - Pharma immune
Immunic is a clinical-stage biotech developing oral medications for chronic inflammatory and autoimmune diseases. Its value is based on expectations. The chart clearly shows how much its market capitalization, based on expectations, exceeds the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
Immunic is a biotech company developing oral medications for chronic inflammatory and autoimmune diseases. The chart shows how the market is pricing in the hope of a more convenient treatment. The company's market capitalization is a bet on the success of its clinical trials, which could lead to the creation of pills instead of injections for millions of patients.
Debts of the company, segment and market as a whole
IMUX - Company debts Immunic Inc.
Immunic is a clinical-stage biopharmaceutical company developing oral therapies for chronic inflammatory and autoimmune diseases. This chart shows how the company is raising capital, including debt, to fund its key clinical programs on the path to commercialization.
Market segment debts - Pharma immune
Immunic is a clinical-stage biopharmaceutical company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. Their goal is to offer a convenient alternative to injections. The chart shows the financial norms for the biotech sector, where companies raise significant capital to conduct lengthy and expensive clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Immunic Inc.
Immunic is a biotech company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. This chart shows the company's debt-to-equity ratio. For a company in clinical trials, this is a key indicator of financial strength and the ability to continue development.
Market segment debt to market segment book capitalization - Pharma immune
Developing oral therapies for autoimmune diseases, like Immunic's, is a Holy Grail for many patients. This chart shows how the biotech sector funds such breakthrough research. It allows us to understand how Immunic, Inc.'s financial model differs from that of injectable drug companies and how it manages R&D risks.
Debt to book value of all companies in the market
Immunic develops oral medications for the treatment of chronic inflammatory and autoimmune diseases. Like many biotech companies, they are actively investing in R&D. The chart shows how their debt strategy for funding clinical trials compares to the overall market.
P/E of the company, segment and market as a whole
P/E - Immunic Inc.
This chart shows the valuation of Immunic, Inc., a clinical-stage biopharmaceutical company developing oral therapies for autoimmune diseases. Its value is determined not by current revenue, but by investors' faith in its scientific platform and the potential of its developments.
P/E of the market segment - Pharma immune
This metric represents the average valuation for the biotech sector in which Immunic operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding autoimmune disease treatments.
P/E of the market as a whole
Immunic is a biotech company developing small-molecule drugs for the treatment of chronic inflammatory and autoimmune diseases. Its lead candidate is aimed at treating multiple sclerosis. This chart shows the overall risk appetite. It helps understand how the market views Immunic's potential compared to existing treatments and how clinical news impacts its valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Immunic Inc.
Immunic is a biotech company developing oral small-molecule drugs for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis and ulcerative colitis. The company's future depends on the success of its clinical programs. This chart shows how investors view the potential of its lead drug to become a convenient oral alternative to injections.
%20P%2FE%20Immunic%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Immunic-Inc.&v=1772567899733 "Chart of the company's future (projected) P/E Immunic Inc.")
Future (projected) P/E of the market segment - Pharma immune
Immunic is a biotech company developing small-molecule, orally administered drugs for the treatment of chronic inflammatory and autoimmune diseases. The goal is to replace injections with pills. The chart reflects sector expectations, helping to assess the market's confidence in the potential of Immunic's developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772567899781 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Immunic is a biotech company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis and ulcerative colitis. This chart of general expectations illustrates investor sentiment toward the biotech. Market optimism and risk appetite are necessary to fund long-term, expensive research aimed at improving the quality of life for millions of patients.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772567899813 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Immunic Inc.
Immunic is a clinical-stage biotech company developing oral therapies for chronic inflammatory and autoimmune diseases. This chart shows the cost of advancing its pipeline of candidates through clinical trials. Future profitability depends on the success of these trials, particularly its lead drug for multiple sclerosis.
Profit of companies in the market segment - Pharma immune
Vicarious Surgical Inc. is developing a next-generation robotic surgical system. Profitability in this sector depends on competition from giant Intuitive Surgical and the adoption of the technology by surgeons. This chart illustrates how breakthrough innovations in medical technology can create huge markets but require colossal investment and high barriers to entry.
Overall market profit
Immunic is a biotech company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. Currently in late-stage clinical trials, the company is approaching the point where its research and development could be translated into a commercial product, which would completely transform its profile.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Immunic Inc.
Immunic, Inc. is a biotechnology company developing small-molecule, orally administered therapies for chronic inflammatory and autoimmune diseases. Its revenue forecast is dependent on the success of clinical trials. This chart shows analyst expectations for its lead drug candidate and its market potential.
%20profit%20of%20the%20company%20Immunic%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Immunic-Inc.&v=1772567899900 "Graph of future (projected) profit of the company Immunic Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis and ulcerative colitis. This chart shows profitability projections for the biotech sector. It reflects the enormous need for convenient and effective treatments for these debilitating diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772567899912 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Immunic, Inc. is a biotech company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. Its success depends on clinical data. This earnings forecast chart is important for assessing overall investor sentiment and their willingness to fund long-term, risky projects in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772567899944 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Immunic Inc.
Immunic is a biotech company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis and ulcerative colitis. Although it has no commercial revenue, its valuation reflects investor expectations for the success of its lead drug candidate in late-stage clinical trials.
P/S market segment - Pharma immune
Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis and ulcerative colitis. This chart shows the average valuation in the sector, providing an indication of the market's perception of Immunic's revenue potential.
P/S of the market as a whole
Immunic is a biopharmaceutical company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis and ulcerative colitis. This chart, reflecting the average estimated real revenue, clearly highlights how biotech investments are betting on scientific breakthroughs in immunology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Immunic Inc.
Immunic is a biopharmaceutical company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. This chart reflects investor expectations for the future success of its lead candidate. The valuation is based on the sales potential of the drug, which could become a convenient alternative to injectable treatments.
%20P%2FS%20Immunic%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Immunic-Inc.&v=1772567900120 "The graph of the company's future (projected) P/S Immunic Inc.")
Future (projected) P/S of the market segment - Pharma immune
Immunic, Inc. is a biopharmaceutical company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis and ulcerative colitis. The chart shows how the market estimates Immunic's future sales, reflecting the potential of its developments to improve the quality of life for millions of patients.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772567900135 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Market sentiment regarding future revenue depends on progress in the treatment of autoimmune diseases. Immunic develops oral medications for conditions such as multiple sclerosis and ulcerative colitis. Their goal is to offer patients a convenient and effective alternative to injectables, which supports confidence in the innovative potential of the pharmaceutical industry.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772567900159 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Immunic Inc.
Immunic is a clinical-stage biopharmaceutical company developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. Currently, its revenue is generated not from sales but from payments under collaboration agreements. This chart reflects progress in research and partnerships.
Sales of companies in the market segment - Pharma immune
Immunic is a biopharmaceutical company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis and ulcerative colitis. This chart reflects overall revenue in the immunology pharmaceutical sector. It demonstrates the enormous demand for the convenient and effective treatments that Immunic strives to offer patients.
Overall market sales
Immunic is a clinical-stage biopharmaceutical company developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. Its value is determined by the potential of its clinical programs. This overall economic outlook influences investor willingness to finance long-term and risky projects in the biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Immunic Inc.
Immunic is a biotech company developing oral small-molecule drugs for the treatment of chronic inflammatory and autoimmune diseases. Success depends on clinical data. The chart shows speculative revenue projections, betting on the company's ability to offer a convenient alternative to injectables.
%20sales%20of%20the%20company%20Immunic%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Immunic-Inc.&v=1772567900506 "Schedule of future (projected) sales of the company Immunic Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Immunic is a biopharmaceutical company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis and ulcerative colitis. This chart displays projected sales for the entire immunological pharmaceutical segment, highlighting overall growth expectations for this cutting-edge field of medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772567900556 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Immunic is a clinical-stage biopharmaceutical company developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. Its valuation is dependent on the success of its clinical programs. This general economic activity profile influences investor willingness to finance long-term and risky projects in the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772567900629 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Immunic Inc.
Immunic is a biotechnology company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. This metric is a financial reflection of its scientific activity. It demonstrates the amount of investment in clinical trials required to bring a new generation of drugs to market.
Market segment marginality - Pharma immune
Immunic is a clinical-stage biopharmaceutical company developing oral therapies for chronic inflammatory and autoimmune diseases. This metric reflects its operational structure and level of investment in research relative to other immunology companies, which is important for assessing its long-term potential.
Market marginality as a whole
Immunic is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for the treatment of chronic inflammatory and autoimmune diseases. Their approach is selective oral immunomodulation. Their success depends on research data. This overall profitability curve is important for them in terms of the overall investment climate in the biotech sector.
Employees in the company, segment and market as a whole
Number of employees in the company Immunic Inc.
Immunic is a clinical-stage biotech company developing oral therapies for chronic inflammatory and autoimmune diseases. This chart shows how the company is scaling up its scientific and clinical teams to conduct several costly Phase III trials, a key step before market entry.
Share of the company's employees Immunic Inc. within the market segment - Pharma immune
Immunic develops oral medications for the treatment of chronic inflammatory and autoimmune diseases. This chart shows the percentage of leading immunologists working on small molecules that the company attracts. Its team strives to create convenient and effective tablets to combat diseases such as multiple sclerosis.
Number of employees in the market segment - Pharma immune
Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. This chart shows overall employment in the immunology research sector. It illustrates the drive to create convenient tablet formulations for diseases that often require injections.
Number of employees in the market as a whole
Immunic, Inc. is a biotechnology company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases such as multiple sclerosis and ulcerative colitis. This chart illustrates the dynamics of the labor market, where the knowledge-intensive biotechnology sector is a vital source of innovation and requires a constant supply of talented scientists and physicians.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Immunic Inc. (IMUX)
Immunic, Inc. is a biopharmaceutical company developing small-molecule drugs for the treatment of chronic inflammatory and autoimmune diseases. This chart demonstrates the market's high valuation of its scientific potential. High market capitalization per employee is the norm, as investors see value in the company's pipeline rather than in current operating metrics.
%20of%20the%20company%20Immunic%20Inc.%20(IMUX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Immunic-Inc.-IMUX&v=1772567900838 "Chart of market capitalization per employee (in thousands of dollars) of the company Immunic Inc. (IMUX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Immunic is a biotech company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. Their key asset is their pipeline of molecules in various stages of clinical trials. This metric reflects how the market perceives their scientific potential. Their high market capitalization per employee reflects their bet that their developments will become successful drugs.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772567900873 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral therapies for chronic inflammatory and autoimmune diseases. Its valuation is dependent on the success of its lead candidate. This metric reflects how investors assess the potential of a single product to change patients' lives and become a blockbuster.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772567900903 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Immunic Inc. (IMUX)
Immunic is a clinical-stage biotech R&D company developing oral medications for chronic inflammatory and autoimmune diseases. This chart shows their capital burn rate—the net loss (costs of clinical trials) per scientist.
%20Chart%20Immunic%20Inc.%20(IMUX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Immunic-Inc.-IMUX&v=1772567900970 "Company Profit Per Employee (in thousands of dollars) Chart Immunic Inc. (IMUX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Immunic is a clinical-stage biotech focused on treating autoimmune diseases. Like most biotechs in the R&D phase, this metric is currently negative. This chart provides a guide to the future. Success will depend on whether their research team can create a drug that delivers profitability above the industry standard.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772567901051 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Immunic (IMUX) is a clinical-stage biotech company developing oral medications for chronic inflammatory and autoimmune diseases. This chart illustrates the economics of their R&D. Their entire research team is working on future products, resulting in negative margins before they are commercialized.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772567901109 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Immunic Inc. (IMUX)
For Immunic, a biotech company developing oral therapies for immune diseases, this chart shows progress in clinical trials. Future revenue growth per employee depends on the success of its lead candidate and partnerships.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Immunic-Inc.-IMUX&v=1772567901135 "Sales chart per company employee Immunic Inc. (IMUX)")
Sales per employee in the market segment - Pharma immune
Immunic is a clinical-stage biopharmaceutical company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. This is R&D. This metric reflects the average revenue per employee in the segment. It helps assess how productive their R&D team is compared to other biotechs in the immunology field.
Sales per employee for the market as a whole
Immunic (IMUX) is a clinical-stage biopharmaceutical company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases. Currently, its staff consists entirely of researchers. This metric is critical for IMUX: it's at zero. Its future growth will reflect the success of its R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company Immunic Inc. (IMUX)
Immunic is a clinical-stage biotech developing oral drugs for autoimmune diseases. Its lead candidate failed in a pivotal trial. This chart shows how many investors are betting that the company's remaining programs will also fail, rendering its scientific platform untenable.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Immunic-Inc.-IMUX&v=1772567901205 "Short Shares Chart for the Company Immunic Inc. (IMUX)")
Shares shorted by market segment - Pharma immune
Immunic (IMUX) is a biopharmaceutical company developing oral medications for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis. This chart summarizes the bearish bets on the immunobiotech sector. It shows the overall market pessimism regarding the high level of competition and failure rates in this field.
Shares shorted by the overall market
Immunic is a clinical-stage biotech company focused on immunology. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing that IMUX will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Immunic Inc. (IMUX)
This chart demonstrates Immunic's high sensitivity to trial data. The company develops oral drugs for the treatment of autoimmune diseases (multiple sclerosis, psoriasis). The publication of strong Phase 2 or 3 data triggers explosive "overheating" (above 70). Any doubts about the efficacy or safety of their key molecules immediately send the oscillator into "oversold" territory.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Immunic-Inc.-IMUX&v=1772567901314 "RSI 14 indicator chart for the company's stock Immunic Inc. (IMUX)")
RSI 14 Market Segment - Pharma immune
Immunic (IMUX) is a biotech (Germany/USA), an immune system "suppressor." They develop *oral* (tablet) drugs for the treatment of *autoimmune* diseases (multiple sclerosis, psoriasis). The "Pharma immune" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this *entire* segment. It is vital to understand: is IMUX's growth due to their R&D, or is *the entire* biotech "overheated"?
RSI 14 for the overall market
For Immunic, a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMUX (Immunic Inc.)
Immunic is a German biopharmaceutical company developing oral (tablet) drugs for the treatment of chronic inflammatory and autoimmune diseases, including multiple sclerosis. This chart shows the speculative average price target from analysts based on their confidence in this R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMUX-Immunic-Inc.&v=1772567901535 "A chart showing analyst consensus forecasts for the expected stock price. IMUX (Immunic Inc.)")
The difference between the consensus estimate and the actual stock price IMUX (Immunic Inc.)
IMUX - Immunic is a German biotech company developing oral (tablet-based) drugs for the treatment of chronic inflammatory and autoimmune diseases. This chart clearly demonstrates the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in the company's R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMUX-Immunic-Inc.&v=1772567901572 "A chart showing the difference between the consensus forecast and the actual stock price. IMUX (Immunic Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Immunic (IMUX) is a German biotech company developing oral medications (tablets) for the treatment of chronic autoimmune diseases such as multiple sclerosis. This chart shows analysts' overall expectations for the immunopharma sector. It reflects whether experts believe R&D success in this competitive field.
Analysts' consensus forecast for the overall market share price
Immunic (IMUX) is a biotech company developing oral (tablet-based) therapies for chronic inflammatory and autoimmune diseases. This chart shows the overall risk appetite. For Immunic, a high-risk clinical-stage company, overall market optimism is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Immunic Inc.
Immunic (IMUX) is a clinical-stage biotech focused on immunology. They are developing oral (tablet) drugs for the treatment of chronic inflammatory diseases (multiple sclerosis, lupus). This chart represents pure R&D betting. Its valuation reflects the market's faith in their scientific platform (inhibitors) and the data from their (very risky) clinical trials.
AKIMA Market Segment Index - Pharma immune
Immunic is a biotech company developing oral medications (in tablet form) for the treatment of chronic inflammatory and autoimmune diseases, such as multiple sclerosis. This chart shows the average index for the immunopharmaceutical sector. It provides investors with a benchmark for how Immunic's performance compares to the sector average.
The AKIM Index for the overall market
Immunic is a biotech company developing oral treatments for chronic inflammatory and autoimmune diseases (such as multiple sclerosis). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this late-stage clinical research company stacks up against the backdrop of overall economic trends and competition.
